Introduction
============

Drug-eluting balloon (DEB) angioplasty with a paclitaxel-coated balloon catheter is an effective treatment option in patients with instent restenosis (ISR) after a drug-eluting stent (DES). We describe a case in which the \'no-reflow\' phenomenon developed after DEB angioplasty of a DES ISR lesion. Coronary flow was restored after intracoronary administration of nicorandil.

Case
====

A 74-year-old man with a history of hypertension and on regular medication for 10 years had accelerating angina for 2 weeks. Six months earlier, he had accelerating chest pain for 1 month, which necessitated admission. His right coronary angiogram revealed diffuse severe stenosis involving the proximal to distal right coronary artery (RCA) ([Fig. 1A](#F1){ref-type="fig"}), which was treated with two overlapping DESs extending from the distal to the proximal RCA (3.0×38 mm and 3.0×30 mm, Endeavor™ Resolute™ stent; Medtronic Vascular, Santa Rosa, CA, USA) ([Fig. 1B](#F1){ref-type="fig"}). A platelet function assay showed 588 ARU and P2Y12 inhibition was 244 PRU (34%). He was discharged with dual antiplatelet therapy.

Six months after the index procedure, he had recurrent chest pain and a repeat angiogram showed diffuse ISR with Thrombolysis in Myocardial Infarction (TIMI) 2 distal flow ([Fig. 1C](#F1){ref-type="fig"}) with pressure damping despite the use of a 5 Fr guiding catheter. Percutaneous coronary intervention was attempted. After balloon dilation with a 2.0 mm balloon, intravascular ultrasound revealed diffuse neointimal proliferation, but neither stent fracture nor overlap free segments were present. Sequential predilation of the distal to proximal RCA was performed with a 3.0×20 mm balloon. After balloon dilation with a 3.0 mm balloon, the RCA showed a stent-like result (less than 20% diameter stenosis with TIMI 3 flow) ([Fig. 2A](#F2){ref-type="fig"}). DEB ballooning was done at the mid to distal RCA with a SeQuent® Please (B. Braun Medical Inc., Melsungen, Germany) paclitaxel-eluting balloon 3.0×30 mm deployed at 8 atm/40 seconds ([Fig. 2B](#F2){ref-type="fig"}). After DEB ballooning, a no-reflow phenomenon developed with chest pain ([Fig. 2C](#F2){ref-type="fig"}). After intracoronary administration of 5 mg of nicorandil (dissolved in 10 mL of 0.9% saline), the distal flow was restored gradually. The final angiogram, taken 5 minutes after development of the no-reflow, showed TIMI 3 flow ([Fig. 2D](#F2){ref-type="fig"}).

The following cardiac enzyme and troponin remained within the normal range. The patient had an uneventful recovery and was discharged home on the following day.

Discussion
==========

Treatment of coronary ISR with a paclitaxel-coated balloon catheter is known to be at least as effective as a paclitaxel-eluting stent[@B1] without the disadvantages of the polymeric matrix that may induce inflammation and thrombosis.[@B2] The DEBs used in this case are coated with the free drug. To enhance the dissolution of the drug, a small amount of radiographic contrast agent is added to the coating.[@B2]-[@B4]

In this case, the angiogram after the predilation with a 3.0 mm balloon showed normal distal flow, but after DEB inflation for 40 seconds, a no-reflow phenomenon developed. Thus, although it remains possible that the findings were coincidental, it is suggested that a \'no-reflow\' phenomenon can develop in some patients treated with a DEB. The no-reflow phenomenon was originally described in patients with ST-segment elevation myocardial infarction (ST-EMI) to describe microvascular obstruction and reduced myocardial flow after opening an occluded artery.[@B5][@B6] The pathogenesis of no-reflow is heterogenous, but distal embolization, ischemia-reperfusion injury, increased microvascular impedance to flow or microvascular spasm was suggested. One possible explanation of no-reflow after DEB angioplasty is related to paclitaxel. A recent study of paclitaxel-coated balloons in a porcine model showed that the paclitaxel-coated balloon is associated with impaired vasodilatory responses to acetylcholine distal to the treated segments.[@B7] The other possible explanation is related to the coating. The coating of a DEB contains a non-ionic water-soluble monomeric contrast agent (iopromide), which may cause vasospasm[@B8] or coronary vasoconstrictive response in atherosclerotic segments in patients with coronary artery disease.[@B9] Recent clinical studies have demonstrated the beneficial effects of nicorandil, an adenosine triphosphate-sensitive potassium channel opener, on no-reflow in patients with STEMI[@B10][@B11] or during rotational atherectomy.[@B12] The no-reflow phenomenon disappe-ared after nicorandil administration in this case. This suggests that nicorandil could be helpful in eliminating the no-reflow phenomenon in such a case.
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![Right coronary angiogram. A: right coronary angiogram shows diffuse severe stenosis involving proximal to distal right coronary artery (RCA). B: final result of initial percutaneous coronary intervention using two overlapping stents. C: follow-up right coronary angiogram shows diffuse severe in-stent restenosis involving proximal to distal RCA.](kcj-42-431-g001){#F1}

![Right coronary angiogram. A: after balloon dilation with a 3.0 mm balloon, the right coronary artery shows stent-like result (less than 20% diameter stenosis with Thrombolysis in Myocardial Infarction 3 flow). B: drug-eluting balloon (DEB) ballooning with a paclitaxel-eluting balloon 3.0×30 mm deployed at 8 atm/40 seconds. C: after DEB ballooning, the coronary angiogram shows no-reflow phenomenon. D: final angiogram shows restoration of distal flow after intracoronary nicorandil.](kcj-42-431-g002){#F2}
